Peptide
SS-31
SaveElamipretide, a mitochondria-targeted tetrapeptide that concentrates in the inner mitochondrial membrane to stabilize cardiolipin and improve oxidative phosphorylation.
Quick verdict
Advanced clinical pipeline for mitochondrial myopathies (Barth syndrome) and heart failure. Phase III results have been mixed.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
Phase II/III trials for Barth syndrome, primary mitochondrial myopathy, and heart failure. Barth syndrome data were promising; heart failure phase III (PROGRESS-HF) did not meet primary endpoint.
Benefits
- Mitochondrial-targeted mechanism well characterized
- Improved cardiac function in Barth syndrome studies
- Potential for broad mitochondrial disease applications
Dosage notes
Clinical trials: 4–40 mg subcutaneously daily. Not commercially available.
Side effects
- Injection-site reactions
- Headache
- Contact urticaria at injection site
Who should be cautious
Investigational drug. Not approved. Mixed phase III results raise efficacy questions.
What this page cannot tell you
Promising mechanism and phase II data but phase III confirmation has been inconsistent.
Leaderboard scores
- Energy30
- Longevity30
- Recovery25
Write a review
Sign in to write a review.